Pioneering microbiome science for next-generation therapeutics
Our vertically integrated R&D approach combines wet lab research, computational biology, and clinical validation under one roof, enabling rapid translation from discovery to market:
500+ characterized probiotic strains from traditional Indian fermented foods and clinical sources
Whole genome sequences, functional annotations, and metabolic pathway reconstructions
10,000+ publications integrated into queryable semantic network linking strains to health outcomes
Biobank of microbiome samples from healthy and diseased populations for comparative studies
Developing microbiome-guided interventions to address malnutrition in children and pregnant women, and cachexia in cancer and TB patients. Focus on enhancing nutrient absorption, supporting muscle maintenance, and improving growth parameters.
Investigating the role of gut microbiome in cancer treatment outcomes. Developing probiotic formulations that produce medicinal metabolites to enhance drug responsiveness, reduce side effects, and support nutritional status during therapy.
Exploring how gut microbiome influences TB treatment outcomes. Developing adjunct probiotic therapies to improve drug absorption, reduce liver toxicity, enhance immune response, and shorten treatment duration.
Researching microbiome-targeted interventions for type 2 diabetes, obesity, metabolic syndrome, and cardiovascular risk factors. Identifying strains that improve glucose metabolism, reduce visceral fat, and prevent progression from prediabetes to diabetes.
Studying the gut-hormone axis and its impact on reproductive health. Developing probiotic interventions for PCOS, endometriosis, and male and female infertility through microbiome modulation.
Researching probiotic interventions for gastric ulcers, H. pylori infection, GERD, IBS, IBD, and functional digestive disorders. Developing strains that strengthen gut barrier and reduce inflammation.
We employ cutting-edge genomic, metagenomic, and metabolomic approaches to identify novel probiotic strains from diverse sources including traditional Indian fermented foods. Our screening pipeline evaluates strains for safety, stability, therapeutic potential, and compatibility with manufacturing processes.
Our formulation team develops disease-specific probiotic products using evidence-based approaches. We optimize strain combinations, delivery systems, and food matrices to ensure maximum efficacy, stability, and cultural acceptability. Each formulation undergoes rigorous testing for viability, bioavailability, and therapeutic effect.
We conduct rigorous clinical trials to validate the efficacy and safety of our formulations. Our clinical research program includes pilot studies, randomized controlled trials (RCTs), and real-world effectiveness studies in collaboration with leading healthcare institutions and teaching hospitals across India. We follow ICH-GCP guidelines and obtain necessary ethical approvals for all human studies.
Our bioinformatics team builds computational tools and databases to accelerate probiotic discovery and personalization. We develop machine learning models to predict strain efficacy, analyze microbiome data, and identify biomarkers for disease risk and treatment response.
Our vertically integrated manufacturing facility follows Good Manufacturing Practices (GMP) to ensure consistent product quality, safety, and efficacy. We maintain complete control over the production process from strain banking to final product packaging, enabling rapid scale-up and cost-effective production.
We actively collaborate with leading academic institutions, healthcare providers, and research organizations to advance microbiome science and translate discoveries into clinical applications. We welcome new partnerships for joint research projects, clinical trials, and technology development.
© 2026 Leeuwenhoek Biocorporation. All rights reserved.